Clinical Trials in Tennessee

Showing 12741-12760 of 20,239 trials

Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear

NCT02555722

This study is a masked, multi-center, daily wear, monthly replacement, bilateral, randomized, lens blocked (subjects remain in the same lens brand throughout the study) concurrent control study enrolling up to 90 subjects with a study duration of approximately three months. Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control).

Myopia

CooperVision, Inc.92 participantsStarted Sep 2015

San Diego, California, United States • Torrance, California, United States • Denver, North Carolina, United States +3 more locations

COMPLETEDPhase 129 miles

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

NCT02574663

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Pancreatic CancerColorectal CancerRectal Cancer+3 more

TG Therapeutics, Inc.66 participantsStarted Sep 2015

Nashville, Tennessee, United States

COMPLETEDPhase 329 miles

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

NCT01827046

A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).

Intracerebral Hemorrhage

Johns Hopkins University499 participantsStarted Dec 2013

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +81 more locations

Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Find Trials by Condition in Tennessee

Contrast-enhanced Ultrasound of the Kidney

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Brain Tissue Oxygen Monitoring in Traumatic Brain Injury (TBI)

Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

A Study in Advanced Solid Tumors

Study of Ramucirumab in Ovarian Cancer

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma